Ampliphi Biosciences Corp (APHB) Short Interest Update

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) was the target of a large decline in short interest in August. As of August 15th, there was short interest totalling 821,241 shares, a decline of 1.1% from the July 31st total of 830,404 shares. Approximately 5.3% of the shares of the stock are short sold. Based on an average trading volume of 55,262 shares, the days-to-cover ratio is presently 14.9 days.

Shares of APHB opened at $0.97 on Tuesday. Ampliphi Biosciences has a one year low of $0.82 and a one year high of $2.05.

Ampliphi Biosciences (NYSEAMERICAN:APHB) last posted its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.01. Ampliphi Biosciences had a negative net margin of 2,050.00% and a negative return on equity of 31.85%.

Separately, HC Wainwright set a $6.00 target price on Ampliphi Biosciences and gave the stock a “buy” rating in a report on Wednesday, May 16th.

A hedge fund recently bought a new stake in Ampliphi Biosciences stock. Sabby Management LLC acquired a new position in Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 831,961 shares of the biotechnology company’s stock, valued at approximately $907,000. Sabby Management LLC owned about 5.05% of Ampliphi Biosciences at the end of the most recent reporting period.

About Ampliphi Biosciences

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections.

Recommended Story: Relative Strength Index

Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply